Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. PIMA542317

Invitrogen™ Aflibercept Humanized Recombinant Human Monoclonal Antibody
GREENER_CHOICE

Catalog No. PIMA542317
Change view
Click to view available options
Quantity:
100 μg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
PIMA542317 100 μg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
This item is not returnable. View return policy
Catalog No. PIMA542317 Supplier Invitrogen™ Supplier No. MA542317
Only null left
Add to Cart
Add to Cart
This item is not returnable. View return policy

Description

Human Recombinant Monoclonal Antibody

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Biosimilars targeting aflibercept biosimilars such as Yesafili, Opuviz, and Pavblu, function by inhibiting vascular endothelial growth factor (VEGF) pathways, crucial for angiogenesis and vascular permeability. These biosimilars emulate the activity of aflibercept, a recombinant fusion protein that combines portions of VEGF receptor 1 (VEGFR1) and VEGF receptor 2 (VEGFR2) with an immunoglobulin G (IgG) Fc fragment, effectively acting as a decoy receptor for VEGF-A, VEGF-B, and placental growth factor (PlGF). By binding to these growth factors, the biosimilars prevent their interaction with VEGF receptors on the surface of endothelial cells, thereby inhibiting the pathological angiogenesis and increased vascular permeability seen in conditions like neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Clinical studies have shown that biosimilars such as SCD411, SB15, and QL1207 demonstrate comparable efficacy and safety to the reference product, aflibercept, in these indications, offering alternative treatment options that meet rigorous equivalency standards set by regulatory bodies.
TRUSTED_SUSTAINABILITY

Specifications

Antigen Aflibercept Humanized
Applications ELISA
Classification Recombinant Monoclonal
Concentration 2.37 mg/mL
Conjugate Unconjugated
Formulation PBS with no preservative; pH 7.4
Gene Alias EYLEA; Zaltrap
Host Species Human
Immunogen Human VEGFA.
Purification Method Protein A/G
Quantity 100 μg
Regulatory Status RUO
Primary or Secondary Primary
Target Species Human
Content And Storage -20°C, Avoid Freeze/Thaw Cycles
Product Type Antibody
Form Liquid
Isotype IgG1 Fc
Target Molecule Chemical
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.